1 ratings / 4 average

Bevacizumab in the Treatment of Metastatic Breast Cancer

Shari B Goldfarb, MD, Maura N Dickler, MD, and Tiffany A Traina, MD

Proangiogenic factors such as vascular endothelial growth factor (VEGF) regulate tumor angiogenesis, which is necessary for breast cancer development, invasion, growth, and metastasis [1–6]. In addition to being one of the central growth factors responsible for neovascularization, VEGF has prognostic significance. Higher levels of VEGF expression are associated with poor clinical outcomes and reduced disease-free survival (DFS) and overall survival (OS) rates in patients with breast cancer [5–8]. Therefore, VEGF is an appropriate target for the pharmacological inhibition of angiogenesis [9–11].

Return to top

LATEST ARTICLES

Our most popular articles